Celyad Oncology SA News - CYAD

Celyad Oncology receives approximately EUR 9.8m in private placement commitments from historical shareholders

MONT-SAINT-GUIBERT, Belgium, Aug. 24, 2023 (GLOBE NEWSWIRE) -- regulated information / inside information...

Celyad Oncology announces receipt of Nasdaq delisting notice

MONT-SAINT-GUIBERT, Belgium, May 15, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology (Euronext & Nasdaq: CYAD...

Celyad Oncology Announces Intent to Voluntarily Delist American Depository Shares From Nasdaq

MONT-SAINT-GUIBERT, Belgium, May 05, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology (Euronext & Nasdaq: CYAD...

Celyad Oncology announces receipt of Nasdaq initial notification on ADS bid price

MONT-SAINT-GUIBERT, Belgium, April 24, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology (Euronext & Nasdaq: CYAD...

Celyad Oncology announces receipt of Nasdaq notice

MONT-SAINT-GUIBERT, Belgium, April 04, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology (Euronext & Nasdaq: CYAD...

Celyad Oncology appoints Georges Rawadi as its new CEO

MONT-SAINT-GUIBERT, Belgium, March 24, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology (Euronext & Nasdaq: CYAD...

Celyad Oncology reports full year 2022 financial results and recent business highlights

Starting in 2023, Celyad Oncology is now entirely focused on its new business strategy with one clear...

Celyad Oncology to announce full year 2022 financial results and host conference call

MONT-SAINT-GUIBERT, Belgium, March 17, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology (Euronext & Nasdaq: CYAD...

Celyad Oncology announces non-cash impairment

MONT-SAINT-GUIBERT, Belgium, March 15, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology (Euronext & Nasdaq: CYAD...

REPEAT -- Celyad Oncology SA - Letter to Shareholders

MONT-SAINT-GUIBERT, Belgium, March 01, 2023 (GLOBE NEWSWIRE) -- The following is a statement by Celyad...

Celyad Oncology SA - Letter to Shareholders

MONT-SAINT-GUIBERT, Belgium, Feb. 28, 2023 (GLOBE NEWSWIRE) -- The following is a statement by Celyad...

Celyad Oncology announces the publication of data from its Phase 1 THINK study of CYAD-01

MONT-SAINT-GUIBERT, Belgium, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology (Euronext & Nasdaq: CYAD...

Celyad Oncology provides fourth quarter 2022 business update and 2023 outlook

Celyad Oncology has implemented a strategic shift from an organization focused on clinical development to one...

Celyad Oncology provides an update on its strategic business model, continuing to focus on opportunities to fully harness the true potential of its proprietary technology platforms and intellectual property

MONT-SAINT-GUIBERT, Belgium, Dec. 21, 2022 (GLOBE NEWSWIRE) -- Celyad Oncology (Euronext & Nasdaq: CYAD...

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Celyad Oncology SA (CYAD)

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

CYAD News

Celyad Oncology receives approximately EUR 9.8m in private placement commitments from historical shareholders

Celyad Oncology announces receipt of Nasdaq delisting notice

Celyad Oncology Announces Intent to Voluntarily Delist American Depository Shares From Nasdaq

Celyad Oncology announces receipt of Nasdaq initial notification on ADS bid price

Celyad Oncology announces receipt of Nasdaq notice

Celyad Oncology appoints Georges Rawadi as its new CEO

Celyad Oncology reports full year 2022 financial results and recent business highlights

Celyad Oncology to announce full year 2022 financial results and host conference call

Celyad Oncology announces non-cash impairment

REPEAT -- Celyad Oncology SA - Letter to Shareholders

Celyad Oncology SA - Letter to Shareholders

Celyad Oncology announces the publication of data from its Phase 1 THINK study of CYAD-01

Celyad Oncology provides fourth quarter 2022 business update and 2023 outlook

Celyad Oncology provides an update on its strategic business model, continuing to focus on opportunities to fully harness the true potential of its proprietary technology platforms and intellectual property

CYAD Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Celyad Oncology SA (CYAD) News

Celyad Oncology SA (CYAD)

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

CYAD News

Celyad Oncology receives approximately EUR 9.8m in private placement commitments from historical shareholders

Celyad Oncology announces receipt of Nasdaq delisting notice

Celyad Oncology Announces Intent to Voluntarily Delist American Depository Shares From Nasdaq

Celyad Oncology announces receipt of Nasdaq initial notification on ADS bid price

Celyad Oncology announces receipt of Nasdaq notice

Celyad Oncology appoints Georges Rawadi as its new CEO

Celyad Oncology reports full year 2022 financial results and recent business highlights

Celyad Oncology to announce full year 2022 financial results and host conference call

Celyad Oncology announces non-cash impairment

REPEAT -- Celyad Oncology SA - Letter to Shareholders

Celyad Oncology SA - Letter to Shareholders

Celyad Oncology announces the publication of data from its Phase 1 THINK study of CYAD-01

Celyad Oncology provides fourth quarter 2022 business update and 2023 outlook

Celyad Oncology provides an update on its strategic business model, continuing to focus on opportunities to fully harness the true potential of its proprietary technology platforms and intellectual property

CYAD Discussion

Your Recent History